Realâ€world performance of the <scp>MiniMed 780G</ system in Latin America: Substantial improvement in g technology iteration of the <scp>MiniMed</scp> autom

Diabetes, Obesity and Metabolism 25, 1688-1697 DOI: 10.1111/dom.15023

Citation Report

#	Article	IF	CITATIONS
1	How can we reach the target of glucose control in type 1 diabetes?. Journal of Diabetes, 2023, 15, 462-464.	1.8	0
2	Real-World Performance of First- Versus Second-Generation Automated Insulin Delivery Systems on a Pediatric Population With Type 1 Diabetes: A One-Year Observational Study. Journal of Diabetes Science and Technology, 0, , .	2.2	1
3	Twelveâ€month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closedâ€loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 3212-3222.	4.4	0
4	Results From a Virtual Clinic for the Follow-up of Patients Using the Advanced Hybrid Closed-Loop System. Journal of Diabetes Science and Technology, 0, , .	2.2	1
5	Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780Gâ,,¢ in Children, Adolescents and Young Adults: A Systematic Review. Diabetes Therapy, 0, , .	2.5	0
6	7. Diabetes Technology: <i>Standards of Care in Diabetes—2024</i> . Diabetes Care, 2024, 47, S126-S144.	8.6	4
7	Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities. Diabetes Technology and Therapeutics, 2024, 26, 161-166.	4.4	6
8	Removing Barriers, Bridging the Gap, and the Changing Role of the Health Care Professional with Automated Insulin Delivery Systems. Diabetes Technology and Therapeutics, 2024, 26, 45-52.	4.4	0
9	Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology and Therapeutics, 2024, 26, 53-65.	4.4	0
10	A Peek Under the Hood: Explaining the MiniMedâ,"¢ 780G Algorithm with Meal Detection Technology. Diabetes Technology and Therapeutics, 2024, 26, 17-23.	4.4	0
11	Celebrating the Data from 100,000 Real-World Users of the MiniMedâ,"¢ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technology and Therapeutics, 2024, 26, 32-37.	4.4	0
12	Early Real-World Performance of the MiniMedâ,"¢ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technology and Therapeutics, 2024, 26, 24-31.	4.4	0
13	Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience. Diabetes Technology and Therapeutics, 2024, 26, 190-197.	4.4	0
14	Characteristics Associated With Elevated Time Below Range in Elderly Patients With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal of Diabetes Science and Technology, 0, , .	2.2	Ο